Clinical Trials · NCT06235086
A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
- Enrollment
- 632
- Start date
- Apr 2024
- Locations
- 1 site, China
- Primary endpoint
- Changes in glycosylated hemoglobin (HbA1c) from baseline at 28 weeks of treatment